62373-80-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Methoxyphenoxy)benzaldehyde is used as a building block for the synthesis of tetrahydroisoquinolinones, which are important compounds in the development of pharmaceuticals. These synthesized compounds have potential applications in the treatment of various medical conditions due to their diverse biological activities.
Used in Analytical Chemistry:
3-(4-Methoxyphenoxy)benzaldehyde is used as an internal standard in the determination of hydrolytic activity of pyrethroids by gas chromatography-mass spectrometry. Its stable and clear yellow liquid properties make it an ideal candidate for this application, ensuring accurate and reliable results in the analysis of pyrethroid compounds.

InChI:InChI=1/C14H12O3/c1-16-12-5-7-13(8-6-12)17-14-4-2-3-11(9-14)10-15/h2-10H,1H3

Upstream product

• 5720-07-0 4-methoxyphenylboronic acid 
• 100-83-4 meta-hydroxybenzaldehyde 
• 623-12-1 4-chloromethoxybenzene 
• 3132-99-8 m-bromobenzoic aldehyde 
• 67437-93-8 2-(3-bromophenyl)-[1,3]dioxane 
• 87199-16-4 3-Formylphenylboronic acid 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 117423-75-3 3-(4-methoxyphenoxy)benzoic acid 
• 35065-12-4 3-(4-hydroxyphenoxy)benzoic acid 
• 117424-73-4 3-(4-hydroxyphenoxy)benzoic acid, ethyl ester 
• 117424-75-6 3-(3-allyl-4-hydroxyphenoxy)benzoic acid ethyl ester 
• 117424-74-5 ethyl 3-<4-(allyloxy)phenoxy>benzoate 
• 117424-76-7 ethyl 3-<3-allyl-4-(decyloxy)phenoxy>benzoate 
• 117424-77-8 ethyl 3-<4-(decyloxy)-3-(3-hydroxypropyl)phenoxy>benzoate 
• 117424-78-9 5-(3-Carboxyphenoxy)-2-(decyloxy)benzenepropanoic acid 
• 117424-72-3 5-<3-(ethoxycarbonyl)phenoxy>-2-(decyloxy)benzenepropanoic acid 
• 1099778-07-0 N-(2,2-dimethoxyethyl)-3-(4-methoxyphenoxy)benzylamine hydrochloride 
• 1436713-73-3 (L,Z)-2-(5-(3-(4-methoxyphenoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 

Relevant academic research and scientific papers

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Mycobacterium tuberculosis thymidylate kinase (MtTMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside MtTMPK inhibitors in an effort to diversify MtTMPK inhibitor chemical space. We here report a new series of MtTMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by two co-crystal structures of MtTMPK in complex with developed inhibitors. These efforts furnished the most potent MtTMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the MtTMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.

Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure

The co-crystal structure of Compound 6b with tubulin was prepared and solved for indicating the binding mode and for further optimization. Based on the co-crystal structures of tubulin with plinabulin and Compound 6b, a total of 27 novel A/B/C-rings plinabulin derivatives were designed and synthesized. Their biological activities were evaluated against human lung cancer NCI-H460 cell line. The optimum phenoxy-diketopiperazine-type Compound 6o exhibited high potent cytotoxicity (IC50 = 4.0 nM) through SAR study of three series of derivatives, which was more potent than plinabulin (IC50 = 26.2 nM) and similar to Compound 6b (IC50 = 3.8 nM) against human lung cancer NCI-H460 cell line. Subsequently, the Compound 6o was evaluated against other four human cancer cell lines. Both tubulin polymerization assay and immunofluorescence assay showed that Compound 6o could inhibit microtubule polymerization efficiently. Furthermore, theoretical calculation of the physical properties and molecular docking were elucidated for these plinabulin derivatives. The binding mode of Compound 6o was similar to Compound 6b based on the result of molecular docking. The theoretical calculated LogPo/w and PCaco of Compound 6o were better than Compound 6b, which could enhance its cytostatic activity. Therefore, Compound 6o might be developed as a novel potent anti-microtubule agent.

Cinnamonitrile adjuvants restore susceptibility to β-lactams against methicillin-resistant staphylococcus aureus

β-Lactams are used routinely to treat Staphylococcus aureus infections. However, the emergence of methicillin-resistant S. aureus (MRSA) renders them clinically precarious. We describe a class of cinnamonitrile adjuvants that restore the activity of oxacillin (a penicillin member of the β-lactams) against MRSA. The lead adjuvants were tested against six important strains of MRSA, one vancomycin-intermediate S. aureus (VISA) strain, and one linezolid-resistant S. aureus strain. Five compounds out of 84 total compounds showed broad potentiation. At 8 μM (E)-3-(5-(3,4-dichlorobenzyl)-2-(trifluoromethoxy)phenyl)-2-(methylsulfonyl)acrylonitrile (26) potentiated oxacillin with a >4000-fold reduction of its MIC (from 256 to 0.06 mg·L-1). This class of adjuvants holds promise for reversal of the resistance phenotype of MRSA.

Probing the Hydrophobic Binding Pocket of G-Protein-Coupled Lysophosphatidylserine Receptor GPR34/LPS1 by Docking-Aided Structure-Activity Analysis

The ligands of certain G-protein-coupled receptors (GPCRs) have been identified as endogenous lipids, such as lysophosphatidylserine (LysoPS). Here, we analyzed the molecular basis of the structure-activity relationship of ligands of GPR34, one of the LysoPS receptor subtypes, focusing on recognition of the long-chain fatty acid moiety by the hydrophobic pocket. By introducing benzene ring(s) into the fatty acid moiety of 2-deoxy-LysoPS, we explored the binding site's preference for the hydrophobic shape. A tribenzene-containing fatty acid surrogate with modifications of the terminal aromatic moiety showed potent agonistic activity toward GPR34. Computational docking of these derivatives with a homology modeling/molecular dynamics-based virtual binding site of GPR34 indicated that a kink in the benzene-based lipid surrogates matches the L-shaped hydrophobic pocket of GPR34. A tetrabenzene-based lipid analogue bearing a bulky tert-butyl group at the 4-position of the terminal benzene ring exhibited potent GPR34 agonistic activity, validating the present hydrophobic binding pocket model.

ANTI-MALIGNANT TUMOR AGENT COMPOSITION

To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

Amino acid promoted ullmann type reaction with low catalyst loading via microwave technology

This work describes CuBr-catalyzed cross-coupling of sterically hindered phenols with substituted aryl halides and hetero aryl halides under microwave conditions using commercially available amino acids as the reaction promoters and K3PO4 as the base. Thi

AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS

An aromatic amino acid derivative represented by the formula ( I ) or its pharmacologically acceptable salt: wherein,R1 is a hydrogen atom or an amino-protecting group,R2 is a halogen atom or an alkyl, aralkyl or aryl group,R3 is 1○ a hydrogen atom, 2○ an aroylamino group, 3○ a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. 4○ a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, 5○ an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, 6○ an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; 1 is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.

Compositions containing aromatic aldehydes and their use in treatments

Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.

Isoquinoline compound melanocortin receptor ligands and methods of using same

The invention relates to melanocortin receptor ligands and methods of using the ligands to alter or regulate the activity of a melanocortin receptor. The invention further relates to tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands and as agents for controlling cytokine-regulated physiologic processes and pathologies, and combinatorial libraries thereof.

PHARMACOLOGICALLY ACTIVE TRIAZINONES

The compounds are substituted 1,2,4-triazin-5-ones which are histamine H 2-antagonists. Two specific compounds of the present invention are 3-2-(5-methyl-4-imidazolylmethylthio)ethylamino!-6-(3-methoxybenzyl)-1,2, 4-tr iazin-5-one and 3-2-(5-methyl-4-imidazolylmethylthio)ethylamino!-6-(3-pyridylmethyl)-1,2,4-tr iazin-5-one.